Of note, LYT-200, a human IgG4 mAb targeting GAL-9 (Figure 3B), that has been reported to inhibit tumor growth in mice models, improve survival, and enhance the quality of the immune environment [175], is currently in an adaptive Phase I/II clinical trial (NCT04666688, https://clinicaltrials.gov/, last accessed 31 October 2024) for relapsed or refractory solid tumors. Here, LGALS9 is linked to neoplasm.